Related Experiment Video
Updated: Jun 9, 2025
Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
Published on: March 17, 2023
Cell specific mitochondria targeted metabolic alteration for precision medicine
Akash Ashokan1,2, Michael Birnhak1, Bapurao Surnar1,2
1NanoTherapeutics Research Laboratory, Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA. shantadhar@med.miami.edu.
Abstract:
Mitochondria play important roles in the maintenance of cellular health. In cancer, these dynamic organelles undergo significant changes in terms of membrane hyperpolarization, altered metabolic functions, fusion-fission balance, and several other parameters. These alterations promote cancer growth, proliferation and spread, and the eventual development of metastatic disease and therapeutic resistance. Thus, routing therapeutics to the mitochondrial compartments can be one of the most promising methodologies for tackling such changes to achieve cancer control. Over the last decade, targeted cancer medicine has experienced tremendous growth, enabling the targeting of mitochondria for greater therapeutic specificity. Here, we demonstrate a feasibility method to specifically target the mitochondria of prostate cancer cells. We achieve such dual targeting by utilizing two functionalized polymers and constructing a single blended nanoparticle (NP). Such a targeting strategy was developed utilizing a polymeric platform that differed in terms of the length of the amphiphilic portions, the linker between the hydrophobic portions, and the attached targeting moieties. In doing this, we demonstrate prostate cancer specific mitochondrial delivery of a chemotherapeutic prodrug to create repair-resistant adducts within mitochondrial DNA promoting cellular death. This article documents the synthetic strategy, optimization of blended NPs for cell specific mitochondria targeting, and the utility of the proof-of-concept design was demonstrated using a combination of analytical and in vitro studies.
Insights
Researchers developed targeted nanoparticles to deliver chemotherapy directly to prostate cancer cell mitochondria. This novel approach aims to induce cell death by creating repair-resistant DNA adducts, offering a promising strategy for cancer treatment.
Area of Science:
- Biomedical Engineering
- Cancer Biology
- Nanotechnology
Background:
- Mitochondria are crucial for cellular health but undergo significant alterations in cancer, promoting tumor growth and therapeutic resistance.
- Targeting mitochondria offers a promising strategy for cancer control by addressing these altered cellular functions.
- Targeted cancer medicine has advanced, enabling specific delivery of therapeutics to mitochondria.
Purpose of the Study:
- To develop a feasible method for specifically targeting prostate cancer cell mitochondria.
- To demonstrate the delivery of a chemotherapeutic prodrug to mitochondria for enhanced cancer therapy.
- To create repair-resistant adducts within mitochondrial DNA to induce cancer cell death.
Main Methods:
- Constructed a single blended nanoparticle (NP) using two functionalized polymers for dual targeting.
- Designed a polymeric platform with variations in amphiphilic portions and linkers for optimized targeting.
- Utilized analytical and in vitro studies to demonstrate the proof-of-concept and efficacy of the NP design.
Main Results:
- Achieved prostate cancer-specific mitochondrial delivery of a chemotherapeutic prodrug.
- Demonstrated the creation of repair-resistant adducts within mitochondrial DNA, leading to cellular death.
- Optimized blended NPs for effective and specific mitochondrial targeting in cancer cells.
Conclusions:
- Developed a novel nanoparticle-based strategy for targeted mitochondrial delivery in prostate cancer.
- This approach shows potential for overcoming therapeutic resistance by inducing mitochondrial DNA damage.
- The study validates a proof-of-concept for dual-targeted, mitochondria-disrupting cancer therapy.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:37Mitochondria